DambrovaM1.JPG (5775 bytes) Maija DAMBROVA
Head of the Laboratory of Pharmacology,
Department of Medicinal Chemistry

Latvian Institute of Organic Synthesis,
Aizkraukles iela 21,
Riga, LV-1006

Phone/Fax: +371 67702408

Date and place of birth: May 3, 1968, Gulbene, Latvia

Fluent in: Latvian (native), English, Russian, and Swedish.

Research interests and activities

    Pharmacology, molecular mechanisms and medicinal chemistry related to the anti-ischemic drugs with novel mechanisms of action, cellular energy metabolism, and inflammation.

    23 SCI publications, 2 patents.
    Presentations at more than 20 international meetings.


2004 MBA, Riga International School of Economics and Business Administration.
                Thesis: “Pharmacoeconomics in Latvia”

2001 Dr. pharm., University of Latvia, Riga, Latvia

1999 PhD in Pharmaceutical Pharmacology, Uppsala University, Uppsala, Sweden
                Thesis: „Discovery of N-hydroxyguanidines as novel electron acceptors of xanthine oxidase. Potential new drugs for treatment of ischaemia and reperfusion injury

1993 Master degree in Biology, University of Latvia, Faculty of Biology, Riga, Latvia


Research experience

2005        Leading researcher, Latvian Institute of Organic Synthesis, Riga, Latvia

2001         Head of Laboratory of Pharmaceutical Pharmacology, Medicinal Chemistry Department, Latvian Institute of
                   Organic   Synthesis, Riga, Latvia

1999         Research scientist, Medicinal Chemistry Department, Latvian Institute of Organic Synthesis, Riga, Latvia

1995-1999        Ph.D. student in Pharmaceutical Pharmacology, Uppsala University, Department of Pharmaceutical
                 Biosciences, Uppsala, Sweden

1995(9 months) Postgraduate exchange student, Department of Pharmaceutical Biosciences, Division of Pharmacology,
                          Uppsala Biomedical Centre, Sweden (Swedish Institute stipend)

1994(7 months) Postgraduate exchange student, Department of Pharmacology and Toxicology, University of Kuopio, Finland
                          (CIMO stipend from Nordic Council)

1993(3 months) Postgraduate exchange student, Institut fur Biochemie und Molekularbiologie, University of Bern, Switzerland

1991         Assistant, Laboratory of Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia

Specialized courses

Honors and Awards

Organizing activities

Teaching experience

Head of Research projects

Representative publications

  1. Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J. Cardiovasc. Pharmacol. 2006;48(6):314-9.
  2. Dambrova M., Chlopicki S., Liepinsh E., Kirjanova O., Gorshkova O., Kozlovski V., Uhlen S., Liepina I., Petrovska R., Kalvinsh I., The methylester of ?-butyrobetaine, but not ?-butyrobetaine itself, induces muscarinic receptor-dependent vasodilatation, Naunyn Schmiedeberg’s Arch. Pharmacol. 2004; 369: 533-539.
  3. Prusis P., Dambrova M., Andrianov V., Rozhkov E., Semenikhina V., Piskunova I., Ongwae E., Lundstedt T., Kalvinsh I., Wikberg J.E., Synthesis and quantitative structure-activity relationship of hydrazones of N-amino-N'-hydroxyguanidine as electron acceptors for xanthine oxidase, J. Med. Chem. 2004; 47:3105-3110.
  4. Muceniece R., Zvejniece L., Kirjanova O., Liepinsh E., Krigere L., Baumane L., Kalvinsh I., Wikberg JE., Dambrova M., ß- and ?-melanocortins inhibit lipopolysaccharide induced nitric oxide production in mice brain, Brain Res. 2004; 995(1):7-13.
  5. Dambrova M., Liepinsh E., Kalvinsh I., Mildronate. Cardioprotective Action through Carnitine-Lowering Effect, Trends Cardiovasc. Med. 2002; 12:275-279.

Last update 26.11.2007